Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 2, pp 527–532 | Cite as

Salvage Surgery for Residual Primary and Locally Recurrent Anal Squamous Cell Carcinoma After Chemoradiotherapy in HIV-positive Individuals

  • Laila Cunin
  • M. Alfa-Wali
  • J. Turner
  • M. Bower
  • L. Ion
  • T. Allen-Mersh
Colorectal Cancer

Abstract

Background

The treatment of anal cancer in human immunodeficiency virus (HIV) patients—as in the general population—is primarily with chemoradiotherapy (CRT), and abdominoperineal resection of residual or recurrent primary disease. The aim of this study was to evaluate the extent of residual primary disease and local recurrence as well as the outcome of salvage surgery after CRT for anal carcinoma in HIV-positive individuals.

Methods

We retrospectively studied HIV-positive anal carcinoma patients treated between February 1989 and November 2012 in a specialist London unit. Extent of residual primary disease, local recurrence after CRT, postoperative complications, and survival after salvage surgery were evaluated.

Results

Complete response was experienced in 44 of 53 (83 %) of HIV patients treated with CRT for anal carcinoma. One patient (2.3 %) developed local recurrence. Nine patients (eight residual primary disease after CRT and one local recurrence) underwent salvage surgery after CRT. There were no perioperative deaths, and perioperative CD4 counts were sustained. Complications occurred in five patients (55 %). Median interval to complete perineal healing was 4 months (range 2–11 months), and median hospital stay was 29 days. Survival (median 16 months) was 25 % at 2 years from salvage surgery.

Conclusions

Results in HIV-positive patients receiving highly active antiretroviral therapy (HAART) suggest that loss of HIV sensitivity to HAART can be avoided, but that there is increased postoperative morbidity that may be related to HIV disease. Survival was comparable to that for salvage therapy after optimal CRT in non-HIV anal carcinoma patients.

Keywords

Human Immunodeficiency Virus Anal Cancer Human Immunodeficiency Virus Disease Anal Carcinoma Anal Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The authors declare no conflict of interest.

References

  1. 1.
    Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB III, Thomas CR Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Alfa-Wali M, Allen-Mersh T, Antoniou A, Tait D, Newsom-Davis T, Gazzard B, et al. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann Oncol. 2012;23:141–7.PubMedCrossRefGoogle Scholar
  5. 5.
    UKCCCR Anal Cancer Trial Working Party; UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348(9034):1049–54.Google Scholar
  6. 6.
    Pocard M, Tiret E, Nugent K, Dehni N, Parc R. Results of salvage abdominoperineal resection for anal cancer after radiotherapy. Dis Colon Rectum. 1998;41:1488–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Eeson G, Foo M, Harrow S, McGregor G, Hay J. Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. Am J Surg. 2011;201:628–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Van Beers BE, Kartheuser A, Delos MA, Grandin C, Detry R, Jamart J, et al. MRI of the anal canal: correlation with histologic examination. Magn Reson Imaging. 1996;14:151–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Anal canal. AJCC cancer staging manual. 7th edn. New York: Springer; 2010. p. 119–26.Google Scholar
  10. 10.
    Torre GC. SCC antigen in malignant and nonmalignant squamous lesions. Tumour Biol. 1998;19:517–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Fox PA, Seet JE, Stebbing J, Francis N, Barton SE, Strauss S, et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Dis. 2005;81:142–6.CrossRefGoogle Scholar
  12. 12.
    Martenson JA, Lipsitz SR, Lefkopoulou M, Engstrom PF, Dayal YY, Cobau CD, et al. Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. Cancer. 1995;76:1731–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Esiashvili N, Landry J, Matthews RH. Carcinoma of the anus: strategies in management. Oncologist. 2002;7:188–99.PubMedCrossRefGoogle Scholar
  14. 14.
    Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J AIDS. 2010;53:124–30.Google Scholar
  15. 15.
    Mariani P, Ghanneme A, De la Rochefordiere A, Girodet J, Falcou MC, Salmon RJ. Abdominoperineal resection for anal cancer. Dis Colon Rectum. 2008;51:1495–501.PubMedCrossRefGoogle Scholar
  16. 16.
    Yuan Y, Xing H, Wang XY, Liu CH, Yang LT, Zheng BF, et al. The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province. Zhonghua Yu Fang Yi Xue Za Zhi. 2011;45:619–24.PubMedGoogle Scholar
  17. 17.
    Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3:e356.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. HIV Med. 2012;13(Suppl 2):1–85.Google Scholar
  19. 19.
    Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, et al. Viral suppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor based regimen. AIDS. 2008;22: 2279–89.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Ferenschild FTJ, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JHW. Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg. 2005; 29(11):1452–7.Google Scholar
  21. 21.
    Maggi P, Bellacosa C, Grattagliano V, Pastore G, Lapadula G. Functional impairments of microcirculation in HIV-positive patients: a laser Doppler fluxometry–based investigation. HIV Clin Trials. 2008;9:428–33.PubMedCrossRefGoogle Scholar
  22. 22.
    Cui Q, Carruthers S, McIvor A, Smaill F, Thabane L, Smieja M. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther. 2010;7:6.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Oursler KK, Goulet JL, Crystal S, Justice AC, Crothers K, Butt AA, et al. Association of age and comorbidity with physical function in HIV-infected and uninfected patients: results from the Veterans Aging Cohort Study. AIDS Patient Care STDS. 2011;25:13–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Renehan AG, O’Dwye ST. Management of local disease relapse. Colorectal Dis. 2011;13:44–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Rouquie D, Lasser P, Castaing M, Boige V, Goere D, Pignon JP, et al. Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients). J Chirig. 2008;145:335–40.CrossRefGoogle Scholar
  26. 26.
    Sunesen KG, Buntzen S, Tei T, Lindegaard JC, Norgaard M, Laurberg S. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol. 2009;16:68–77.PubMedCrossRefGoogle Scholar
  27. 27.
    National Comprehensive Cancer Network Guidelines in Oncology. Anal carcinoma, version 1.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 15 Dec 2012.
  28. 28.
    Salmo E, Haboubi N. Anal cancer: pathology, staging and evidence-based minimum data set. Colorect Dis. 2011;13(Suppl 1):11–20.CrossRefGoogle Scholar
  29. 29.
    Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys. 2010;78:715–21.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Laila Cunin
    • 1
  • M. Alfa-Wali
    • 1
  • J. Turner
    • 1
  • M. Bower
    • 2
    • 3
  • L. Ion
    • 4
  • T. Allen-Mersh
    • 1
    • 3
  1. 1.Department of SurgeryChelsea and Westminster NHS Foundation TrustLondonUK
  2. 2.Department of OncologyChelsea and Westminster NHS Foundation TrustLondonUK
  3. 3.Imperial CollegeLondonUK
  4. 4.Department of Plastic SurgeryChelsea and Westminster NHS Foundation TrustLondonUK

Personalised recommendations